

## **Announcement of New Appointments**

Tokyo – London, 31 March 2006 – Sosei Co. Ltd. [4565, Tokyo Stock Exchange, MOTHERS index] is pleased to announce the following new appointments and changes effective as below.

### **Effective as of 1 April 2006**

*Yoshiyuki YAMAKAWA*

*Appointed as Representative Executive Officer, Executive Vice President and CFO, Head of Japanese Operations*

*(Previously Representative Executive Officer, Executive Vice President and CFO, Head of Administration)*

*Hiroyuki HANADA*

*Appointed as Executive Officer and Executive Vice President, Special Assignment by CEO*

*(Previously Executive Officer, Executive Vice President, R&D)*

### **Effective as of 3 April 2006**

*Julian GILBERT, Ph.D.*

*Appointed as Executive Officer and Executive Vice President, Chief Business Officer*

*(Previously Group Director, Commercial and Strategic Development)*

*Robin BANNISTER, Ph.D.*

*Appointed as Executive Officer and Executive Vice President, Managing Director of Arakis*

*(Previously Managing Director of Arakis)*

- end -

## **Notes to editors**

### ***Julian GILBERT, Ph.D.***

Julian Gilbert co-founded Arakis in March 2000 and served as Commercial Director of Arakis and then Sosei Group Director in charge of Commercial and Strategic Development.

- Former Commercial Development Director & Executive Director, PolyMASC
- Chiroscience Group plc, various positions including Head of Licensing and was concurrently a Project Leader of a number of research and development projects
- Formerly responsible for drug delivery business development at Mundipharma

International and BTG

- Worked in formulation development at SmithKline Beecham
- Studied pharmacy and achieved a Ph.D. in pharmaceuticals from the University of Nottingham

***Robin BANNISTER, Ph.D.***

Robin Bannister co-founded Arakis in March 2000 and served as Research & Development Director and then Managing Director of Arakis.

- Former Director of Preclinical Development at Celltech and at Chiroscience
- Former Senior Synthetic Chemist, SmithKline Beecham
- Studied first degree in chemistry whilst working at SmithKline and then Ph.D. in organic chemistry at Imperial College, London

**Enquiries**

**Sosei Co. Ltd. London Office**

**Tel: +44 (0)207 529 8400**

Julian GILBERT, Chief Business Officer or Toshio MIYASHITA, Vice President

**Sosei Co. Ltd. Tokyo Office**

**Tel: +81-(0)3 5210 3399**

Hiroki MAEKAWA, Director of Corporate Planning

**About Sosei**

Sosei Co. Ltd. is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

In August 2005, Sosei expanded its international presence through the acquisition of the UK-based private biopharmaceutical company Arakis Limited.

For further information about Sosei, please visit [www.osei.com](http://www.osei.com).